According to Histopathologist Dr Imrana Tanvir, the overexpression of HER2 accounts for 25% of breast cancers and can indicate a "shorter survival" for these cancer patients.
Heather Lozada, a HER2 patient, reflects on her breast cancer diagnosis and the care she received at the Lester and Sue Smith Breast Center. Her treatment plan included 6 rounds of chemotherapy.
For elderly patients with HER2 Breast Cancer, researchers evaluated whether dual HER2 inhibition with trastuzumab and pertuzumab plus metronomic cyclophosphamide is superior to dual HER2 inhibition alone among elderly patients with HER2-positive.
According to Mike Bassett, the combination of "'soft' chemotherapy and anti-HER2 therapy" increases survival rates in older patients who have HER2.